Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer

Clinical resistance to the second-generation antiandrogen enzalutamide in castration resistant prostate cancer (CRPC), despite persistent androgen receptor (AR) activity in tumors, highlights the unmet medical need for next generation antagonists. We have identified and characterized tetra-aryl cycl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Chem Biol
Main Authors: Pollock, Julie A., Wardell, Suzanne E., Parent, Alexander A., Stagg, David B., Ellison, Stephanie J., Alley, Holly M., Chao, Christina A., Lawrence, Scott A., Stice, James P., Spasojevic, Ivan, Baker, Jennifer G., Kim, Sung Hoon, McDonnell, Donald P., Katzenellenbogen, John A., Norris, John D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5030124/
https://ncbi.nlm.nih.gov/pubmed/27501397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nchembio.2131
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados